NovoSeven RT 8mg vial approved for hemophilia A or B

NovoSeven RT 8mg vial approved for hemophilia A or B
NovoSeven RT 8mg vial approved for hemophilia A or B
The FDA has approved NovoSeven RT (coagulation Factor VIIa [recombinant] room temperature stable, from Novo Nordisk) in an 8mg vial size. The 8mg vial allows a rapid initiation and administration of NovoSeven RT for those who need a larger dose. In addition, the FDA has also approved the extension of shelf life for all vial sizes from 24 months to 36 months at room temperature.

NovoSeven RT is indicated for the treatment of bleeding episodes in hemophilia A or B patients with inhibitors to FVIII or FIX and in patients with acquired hemophilia; prevention of bleeding in surgical interventions or invasive procedures in hemophilia A or B patients with inhibitors to FVIII or FIX and in patients with acquired hemophilia; treatment of bleeding episodes in patients with congenital Factor VII deficiency and prevention of bleeding in surgical interventions or invasive procedures in patients with congenital FVII deficiency.

NovoSeven RT is already available in 1mg, 2mg, and 5mg vials. The 8mg vial size is expected to be available in November 2010.

For more information call (877) 668-6777 or visit www.novosevenrt.com.